Year None202420232022202120202019201820172016 April 9, 2024 Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR) Go to April 9, 2024 Medicenna Presents Updated Preclinical Data on MDNA113, a First-in-Class, Targeted and Masked Bi-functional anti-PD1-IL2 Superkine, at the 2024 Annual Meeting of the American Association for Cancer Research (AACR) Go to April 4, 2024 Medicenna to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference Go to March 6, 2024 Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting Go to February 14, 2024 Medicenna Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Corporate Update Go to February 13, 2024 Medicenna Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors Go to Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Page 4 Current page 5 Page 6 Next page next › Last page last »
April 9, 2024 Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR) Go to
April 9, 2024 Medicenna Presents Updated Preclinical Data on MDNA113, a First-in-Class, Targeted and Masked Bi-functional anti-PD1-IL2 Superkine, at the 2024 Annual Meeting of the American Association for Cancer Research (AACR) Go to
April 4, 2024 Medicenna to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference Go to
March 6, 2024 Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting Go to
February 14, 2024 Medicenna Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Corporate Update Go to
February 13, 2024 Medicenna Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors Go to
